EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma

EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma

Background Chimeric antigen receptor (CAR) T-cell therapy has demonstrated significant benefits in the treatment of relapsed/refractory multiple myeloma (RRMM). However, these outcomes can be compromised by severe complications, including cytokine release syndrome, immune effector cell-associated ne...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiang Zhou, Patrick Costello, Anita Schmitt, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Max Topp, Hartmut Goldschmidt, Hermann Einsele, Nikhil C Munshi, Marc S Raab, Joseph Kauer, Thomas Hielscher, Niels Weinhold, Mirco J Friedrich, Sandra Sauer, Leo Rasche, Thomas Luft, Jan H Frenking, Vivien Wagner, Elias K Mai, Christian S Michel, Marina Hajiyianni, Iris Breitkreutz, Omar Nadeem, Adam S Sperling
Format: Article
Language:English
Published: BMJ Publishing Group 2024-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/10/e009220.full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items